Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ11151MR)

This product GTTS-WQ11151MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_000629.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3454
UniProt ID	P17181

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11151MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ1123MR	IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	ABBV-927
GTTS-WQ76MR	IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	(131)I-chTNT-1/B
GTTS-WQ3735MR	IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	BAY-1093884
GTTS-WQ253MR	IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	17-1A
GTTS-WQ9133MR	IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	IMGN-289
GTTS-WQ995MR	IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ABBV-383
GTTS-WQ10951MR	IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MBG-453
GTTS-WQ13564MR	IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	PRX-302

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.